Trial Profile
A phase II trial of dociparstat sodium (CX-01) in patients with severe traumatic brain injury
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2017
Price :
$35
*
At a glance
- Drugs Dociparstat sodium (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- 11 Apr 2017 New trial record
- 04 Apr 2017 This trial is expected to begin in 2017, according to a Cantex Pharmaceuticals media release.